Description

Aniracetam is a nootropic ampakine that exhibits anxiolytic and neuroprotective activities. Aniracetam acts as a positive allosteric modulator of AMPA receptors, slowing receptor deactivation; it also acts on D2 receptors, 5-HT2A receptors, and nicotinic acetylcholine receptors (nAChRs), likely displaying agonist activity. Aniracetam decreases anxiety in vivo in the condition fear stress test, elevated plus maze test, and in social interaction tests. Additionally, this compound inhibits H2O2-induced deficits in long-term potentiation and neuron viability. Aniracetam shows some clinical benefit in the enhancement of cognitive deficits associated with stroke and Alzheimer’s disease.

Product Info

Cas No. 72432-10-1

Purity ≥98%

Formula C12H13NO3

Formula Wt. 219.24

Chemical Name 1-(4-Methoxybenzoyl)-2-pyrrolidinone

IUPAC Name 1-(4-methoxybenzoyl)pyrrolidin-2-one

Synonym Ro-13-5057, Draganon, Sarpul  

Melting Point 121-122°C

Solubility Soluble in chloroform and ethyl acetate. Slightly soluble in ethanol. Insoluble in water.

Appearance White or almost White Crystalline Powder

艾美捷Aniracetam #LKT-A5326-25mg是一種促智安帕因， 表現(xiàn)出抗焦慮和神經(jīng)保護(hù)活性.阿尼西坦作為AMPA受體的正變構(gòu)調(diào)節(jié)劑，減緩受體失活;它還作用于 D2 受體、5-HT2A 受體和煙堿乙酰膽堿受體 （nAChRs），可能顯示激動劑活性。Aniracetam在恐懼壓力測試，升高加迷宮測試和社會互動測試中減少體內(nèi)焦慮。此外，該化合物抑制 H2O2 誘導(dǎo)的長期增強(qiáng)和神經(jīng)元活力缺陷.阿尼西坦在增強(qiáng)與中風(fēng)和阿爾茨海默病相關(guān)的認(rèn)知缺陷方面顯示出一些臨床益處。

Aniracetam 參數(shù)說明：

cas#：72432-10-1

純度：≥98%

公式： C12H13NO3

配方重量：219.24

化學(xué)名稱：1-（4-甲氧基苯甲?；?span style="font-family: Calibri;">-2-吡咯烷酮

IUPAC名稱：1-（4-甲氧基苯甲?；┻量┩?span style="font-family: Calibri;">-2-酮

同義詞：Ro-13-5057， 德拉加農(nóng)， 薩普爾

熔點(diǎn)：121-122°C

溶解度：溶于氯仿和乙酸乙酯。微溶于乙醇。不溶于水。

外觀：白色或幾乎白色結(jié)晶粉末

Aniracetam文獻(xiàn)參考：

Wang YF, Li CC, Cai JX. Aniracetam attenuates H2O2-induced deficiency of neuron viability, mitochondria potential and hippocampal long-term potentiation of mice in vitro. Neurosci Bull. 2006 Sep;22(5):274-80. PMID: 17690727.

Jin R, Clark S, Weeks AM, et al. Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci. 2005 Sep 28;25(39):9027-36. PMID: 16192394.

Nakamura K. Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. CNS Drug Rev. 2002 Spring;8(1):70-89. PMID: 12070527.

Nakamura K, Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. PMID: 11412837.

Ito I, Tanabe S, Kohda A, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol. 1990 May;424:533-43. PMID: 1975272.